Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
07:15pm, Tuesday, 27'th Feb 2024
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quali
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
08:30am, Tuesday, 20'th Feb 2024
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality w
The 3 Best Penny Stocks to Buy in February 2024
07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
10:36am, Tuesday, 13'th Feb 2024
The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
01:36pm, Thursday, 08'th Feb 2024
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
Veru Reports Fiscal 2024 First Quarter Financial Highlights
06:30am, Thursday, 08'th Feb 2024
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone—
FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Thursday, 01'st Feb 2024
Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:30am, Wednesday, 31'st Jan 2024
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced ac
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
08:30am, Thursday, 25'th Jan 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
08:30am, Wednesday, 20'th Sep 2023
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
08:30am, Wednesday, 30'th Aug 2023
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral indu
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
09:15am, Thursday, 10'th Aug 2023
Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.28 per share a year ago.
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
08:30am, Thursday, 03'rd Aug 2023
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respi
Veru to Present at the Jefferies Healthcare Conference
08:30am, Wednesday, 24'th May 2023
MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for S
